Current Oncology, Free Full-Text
4.5 (175) · $ 26.50 · In stock
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.
PDF) Corrigendum: Progression-Free Survival in Advanced Ovarian
Cancer Facts & Figures 2023
Prioritising breast cancer theranostics: A current medical longing
Current Oncology, Free Full-Text
Clinicopathological Characteristics and Prognosis of 91 Patients, smbot
Current Oncology, Free Full-Text
Current Oncology, Free Full-Text
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
International Journal of Cancer - Wiley Online Library
Oncology Board Review: Blueprint Study Guide and Q&A (3rd Revised edition) by Francis P. Worden
